Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid Leukemia

Ryan G. Kruger(Arysta LifeScience (France)), Peter J. Tummino(Intarcia Therapeutics (United States)), Scott A. Armstrong(Courant Institute of Mathematical Sciences), Charles F. McHugh(GlaxoSmithKline (United States)), Dominic Suarez(GlaxoSmithKline (United States)), Meagan B. Rouse(GlaxoSmithKline (United States)), Monica Cusan(Memorial Sloan Kettering Cancer Center), Xinrong Tian(GlaxoSmithKline (United Kingdom)), Melissa B. Pappalardi(GlaxoSmithKline (United States)), Thau Ho(GlaxoSmithKline (United States)), Jiri Kasparec(GlaxoSmithKline (United States)), Kimberly N. Smitheman(GlaxoSmithKline (United States)), Kelly Federowicz(GlaxoSmithKline (United States)), Neil W. Johnson(Brandywine Photonics (United States)), Yan Liu(Qingdao University), William H. Miller(Clinical Innovations (United States)), Glenn Van Aller(GlaxoSmithKline (United States)), Jessica L. Schneck(GlaxoSmithKline (United States)), Patrick McDevitt(GlaxoSmithKline (United States)), Helai P. Mohammad(Arysta LifeScience (France)), Jeffrey D. Carson(GlaxoSmithKline (United States))
Blood
November 15, 2013
Cited by 30


Related Papers